JP2006520184A - 組換えタンパク質変種 - Google Patents
組換えタンパク質変種 Download PDFInfo
- Publication number
- JP2006520184A JP2006520184A JP2004547452A JP2004547452A JP2006520184A JP 2006520184 A JP2006520184 A JP 2006520184A JP 2004547452 A JP2004547452 A JP 2004547452A JP 2004547452 A JP2004547452 A JP 2004547452A JP 2006520184 A JP2006520184 A JP 2006520184A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- allergen
- protein variant
- naturally occurring
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 44
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 215
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 210
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 14
- 239000013566 allergen Substances 0.000 claims description 305
- 230000035772 mutation Effects 0.000 claims description 205
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 156
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims description 156
- 101710204410 Scaffold protein Proteins 0.000 claims description 156
- 125000000539 amino acid group Chemical group 0.000 claims description 147
- 150000001413 amino acids Chemical class 0.000 claims description 78
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 56
- 206010020751 Hypersensitivity Diseases 0.000 claims description 55
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 230000007815 allergy Effects 0.000 claims description 44
- 208000026935 allergic disease Diseases 0.000 claims description 35
- 230000028993 immune response Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 229960001340 histamine Drugs 0.000 claims description 28
- 238000002255 vaccination Methods 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 230000001681 protective effect Effects 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 238000001142 circular dichroism spectrum Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000009257 reactivity Effects 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 8
- 102220570133 Histone PARylation factor 1_K32Q_mutation Human genes 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 102220644061 Prostaglandin E synthase 3_E12V_mutation Human genes 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 102220351487 c.133G>A Human genes 0.000 claims description 6
- 102220419563 c.334C>G Human genes 0.000 claims description 6
- 239000000428 dust Substances 0.000 claims description 6
- 102200155721 rs121918464 Human genes 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 102220494450 39S ribosomal protein L16, mitochondrial_T64K_mutation Human genes 0.000 claims description 5
- 102220562498 Methylosome subunit pICln_T65Y_mutation Human genes 0.000 claims description 5
- 102220472834 Proteasomal ATPase-associated factor 1_S14P_mutation Human genes 0.000 claims description 5
- 102220608384 Transcription factor SOX-3_P105A_mutation Human genes 0.000 claims description 5
- 208000030961 allergic reaction Diseases 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102220226015 rs1064795246 Human genes 0.000 claims description 5
- 102220001770 rs137852957 Human genes 0.000 claims description 5
- 102220101150 rs141798398 Human genes 0.000 claims description 5
- 102220321085 rs1554518986 Human genes 0.000 claims description 5
- 102220282902 rs1555618428 Human genes 0.000 claims description 5
- 102200094231 rs587777251 Human genes 0.000 claims description 5
- 102220040076 rs587778166 Human genes 0.000 claims description 5
- 102220027730 rs587779158 Human genes 0.000 claims description 5
- 102220203056 rs753524431 Human genes 0.000 claims description 5
- 102220267363 rs775772074 Human genes 0.000 claims description 5
- 102200157824 rs7764472 Human genes 0.000 claims description 5
- 102220086214 rs864622379 Human genes 0.000 claims description 5
- 102220096699 rs876659444 Human genes 0.000 claims description 5
- 102220323587 rs926718557 Human genes 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000013568 food allergen Substances 0.000 claims description 4
- 102220013898 rs397516801 Human genes 0.000 claims description 4
- 102220046354 rs587782857 Human genes 0.000 claims description 4
- 102220247977 rs758942502 Human genes 0.000 claims description 4
- 102220104240 rs879253869 Human genes 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102220472850 ADP-ribosylation factor-like protein 13B_T35N_mutation Human genes 0.000 claims description 3
- 102220508646 Aldo-keto reductase family 1 member A1_K80M_mutation Human genes 0.000 claims description 3
- 102220613770 Angiotensin-converting enzyme 2_T92Q_mutation Human genes 0.000 claims description 3
- 241000256844 Apis mellifera Species 0.000 claims description 3
- 102220482441 Calcium/calmodulin-dependent protein kinase type 1G_K52D_mutation Human genes 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 102220492954 D-amino acid oxidase activator_R30K_mutation Human genes 0.000 claims description 3
- 102220581535 DNA dC->dU-editing enzyme APOBEC-3G_F74W_mutation Human genes 0.000 claims description 3
- 102220524218 Interferon regulatory factor 6_N88H_mutation Human genes 0.000 claims description 3
- 102220509699 Killer cell lectin-like receptor subfamily B member 1_T60I_mutation Human genes 0.000 claims description 3
- 102220517584 Methyl-CpG-binding domain protein 3-like 2B_S19P_mutation Human genes 0.000 claims description 3
- 102220527891 NADH-cytochrome b5 reductase 2_K10Q_mutation Human genes 0.000 claims description 3
- 102220550343 Netrin receptor UNC5A_K39M_mutation Human genes 0.000 claims description 3
- 102220466461 Olfactory receptor 13C9_T91S_mutation Human genes 0.000 claims description 3
- 102220640029 Proton channel OTOP1_T60V_mutation Human genes 0.000 claims description 3
- 102220509999 Putative POM121-like protein 1_K88R_mutation Human genes 0.000 claims description 3
- 102220491177 Sestrin-1_L44I_mutation Human genes 0.000 claims description 3
- 102220577436 Stromal cell-derived factor 1_K48S_mutation Human genes 0.000 claims description 3
- 102220474586 Ubiquitin-conjugating enzyme E2 D1_K4E_mutation Human genes 0.000 claims description 3
- 102220347004 c.89G>A Human genes 0.000 claims description 3
- 102220423675 c.96G>T Human genes 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000013573 pollen allergen Substances 0.000 claims description 3
- 102200139519 rs104893652 Human genes 0.000 claims description 3
- 102200139525 rs104893653 Human genes 0.000 claims description 3
- 102200017393 rs104894299 Human genes 0.000 claims description 3
- 102200058457 rs121434643 Human genes 0.000 claims description 3
- 102200007939 rs128626231 Human genes 0.000 claims description 3
- 102220264540 rs143494120 Human genes 0.000 claims description 3
- 102220258180 rs1553607617 Human genes 0.000 claims description 3
- 102220289826 rs1555407420 Human genes 0.000 claims description 3
- 102220327611 rs1555604902 Human genes 0.000 claims description 3
- 102220032811 rs367543159 Human genes 0.000 claims description 3
- 102220252689 rs373178770 Human genes 0.000 claims description 3
- 102200051837 rs387907346 Human genes 0.000 claims description 3
- 102220276015 rs782161942 Human genes 0.000 claims description 3
- 102220061202 rs786203440 Human genes 0.000 claims description 3
- 102220088309 rs891107196 Human genes 0.000 claims description 3
- 241001674044 Blattodea Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 210000001728 clone cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 102200056168 rs371443644 Human genes 0.000 claims description 2
- 241000208838 Asteraceae Species 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 241000282373 Panthera pardus Species 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 244000274883 Urtica dioica Species 0.000 claims 1
- 235000009108 Urtica dioica Nutrition 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 146
- 235000001014 amino acid Nutrition 0.000 description 104
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 63
- 229960004784 allergens Drugs 0.000 description 53
- 108010029485 Protein Isoforms Proteins 0.000 description 38
- 102000001708 Protein Isoforms Human genes 0.000 description 38
- 208000010668 atopic eczema Diseases 0.000 description 32
- 230000000172 allergic effect Effects 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 230000003993 interaction Effects 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 230000009260 cross reactivity Effects 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 235000018185 Betula X alpestris Nutrition 0.000 description 11
- 235000018212 Betula X uliginosa Nutrition 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 210000003630 histaminocyte Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002983 circular dichroism Methods 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000003651 basophil Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 230000009830 antibody antigen interaction Effects 0.000 description 6
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 101100163901 Rattus norvegicus Asic2 gene Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000008076 immune mechanism Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
- 229920000856 Amylose Polymers 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000004576 Placental Lactogen Human genes 0.000 description 3
- 108010003044 Placental Lactogen Proteins 0.000 description 3
- 239000000381 Placental Lactogen Substances 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000013574 grass pollen allergen Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 240000004585 Dactylis glomerata Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 206010068355 Oral allergy syndrome Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 241000238675 Periplaneta americana Species 0.000 description 2
- 241000746983 Phleum pratense Species 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 101150006061 neur gene Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000010267 Allergoid Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000208837 Asterales Species 0.000 description 1
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 1
- 101710183938 Barstar Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000007857 Castanea sativa Species 0.000 description 1
- 235000014037 Castanea sativa Nutrition 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 102220645934 Cell surface A33 antigen_N28Q_mutation Human genes 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000219427 Fagales Species 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001510164 Lepidoglyphus destructor Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 101000813258 Paspalum notatum Expansin-B Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001136123 Phalaris aquatica Species 0.000 description 1
- 241000209048 Poa Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 108700042135 Tyrophagus putrescentiae Tyr p 2 Proteins 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102200150393 rs34477820 Human genes 0.000 description 1
- 102220064189 rs34953651 Human genes 0.000 description 1
- 102220097978 rs780920036 Human genes 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002578 wasp venom Substances 0.000 description 1
- 229940045949 wasp venoms Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43568—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from wasps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Insects & Arthropods (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42298302P | 2002-11-01 | 2002-11-01 | |
| DKPA200201686 | 2002-11-01 | ||
| PCT/DK2003/000744 WO2004039834A2 (en) | 2002-11-01 | 2003-10-31 | Recombinant protein variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006520184A true JP2006520184A (ja) | 2006-09-07 |
| JP2006520184A5 JP2006520184A5 (https=) | 2006-11-09 |
Family
ID=35719237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004547452A Pending JP2006520184A (ja) | 2002-11-01 | 2003-10-31 | 組換えタンパク質変種 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7384635B2 (https=) |
| EP (1) | EP2270164A3 (https=) |
| JP (1) | JP2006520184A (https=) |
| CN (1) | CN1714153A (https=) |
| AU (1) | AU2003275941A1 (https=) |
| CA (1) | CA2503886A1 (https=) |
| PL (1) | PL375218A1 (https=) |
| WO (1) | WO2004039834A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023502943A (ja) * | 2019-11-13 | 2023-01-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | エアロアレルゲン関連アレルギーと炎症とを治療するナノエマルジョン組成物 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070665A2 (en) * | 2001-03-02 | 2002-09-12 | The Rockefeller University | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| AT501101B1 (de) * | 2004-12-02 | 2008-01-15 | Biomay Ag | Protein-allergen-derivat |
| ZA200707413B (en) | 2005-03-18 | 2009-01-28 | Cytos Biotechnology Ag | Cat allergen fusion proteins and uses thereof |
| HUE029021T2 (en) | 2005-06-21 | 2017-02-28 | Xoma (Us) Llc | IL-1beta-binding antibodies and fragments thereof |
| WO2008010837A2 (en) * | 2005-12-15 | 2008-01-24 | The Regents Of The University Of California | Noncompetitive immunoassays to detect small molecules |
| EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
| EP2028188A1 (en) * | 2007-08-21 | 2009-02-25 | Biomay AG | Hypoallergenic molecules |
| SI2391650T1 (sl) | 2007-12-20 | 2015-03-31 | Xoma (Us) Llc | Postopki za zdravljenje protina |
| ITMI20111489A1 (it) * | 2011-08-03 | 2013-02-04 | Lofarma Spa | Varianti ipoallergeniche dell'allergene maggiore mal d 1 di malus domestica |
| WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
| RU2597782C1 (ru) * | 2015-08-25 | 2016-09-20 | Василий Николаевич Яковлев | Способ определения содержания продуктов протеолиза в плазме крови и диагностическая тест-система для его осуществления |
| WO2021178572A1 (en) * | 2020-03-03 | 2021-09-10 | The Regents Of The University Of California | Non-invasive detection of salivary autoantibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT401180B (de) * | 1990-08-13 | 1996-07-25 | Biomay Biotech Prod | Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung |
| JP3316535B2 (ja) * | 1995-03-28 | 2002-08-19 | アサヒビール株式会社 | ダニアレルゲンの改変体およびその製造法 |
| DE19810906A1 (de) | 1998-03-13 | 1999-09-16 | Basf Ag | Reaktivfarbstoffe mit einem Kombinationsanker |
| PL194804B1 (pl) * | 1998-03-16 | 2007-07-31 | Alk Abello As | Zrekombinowany alergen, sposób przygotowywania zrekombinowanego alergenu, kompozycja farmaceutyczna oraz zastosowanie zrekombinowanego alergenu do przygotowywania leku do wywoływania odpowiedzi immunologicznej u osobnika i do przygotowywania leku do leczenia, zapobiegania lub osłabiania reakcji alergicznych |
| ATE414773T1 (de) | 2000-11-16 | 2008-12-15 | Alk Abello As | Mutante allergene |
| WO2002070665A2 (en) * | 2001-03-02 | 2002-09-12 | The Rockefeller University | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| US7290199B2 (en) * | 2004-11-19 | 2007-10-30 | International Business Machines Corporation | Method and system for improved buffer utilization for disk array parity updates |
-
2003
- 2003-10-31 CA CA002503886A patent/CA2503886A1/en not_active Abandoned
- 2003-10-31 AU AU2003275941A patent/AU2003275941A1/en not_active Abandoned
- 2003-10-31 PL PL03375218A patent/PL375218A1/xx not_active Application Discontinuation
- 2003-10-31 WO PCT/DK2003/000744 patent/WO2004039834A2/en not_active Ceased
- 2003-10-31 EP EP10181325A patent/EP2270164A3/en not_active Withdrawn
- 2003-10-31 CN CNA2003801039329A patent/CN1714153A/zh active Pending
- 2003-10-31 US US10/698,855 patent/US7384635B2/en not_active Expired - Fee Related
- 2003-10-31 JP JP2004547452A patent/JP2006520184A/ja active Pending
-
2008
- 2008-05-28 US US12/128,181 patent/US20090054625A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023502943A (ja) * | 2019-11-13 | 2023-01-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | エアロアレルゲン関連アレルギーと炎症とを治療するナノエマルジョン組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090054625A1 (en) | 2009-02-26 |
| US7384635B2 (en) | 2008-06-10 |
| EP2270164A3 (en) | 2011-05-04 |
| CA2503886A1 (en) | 2004-05-13 |
| CN1714153A (zh) | 2005-12-28 |
| US20040171116A1 (en) | 2004-09-02 |
| EP2270164A2 (en) | 2011-01-05 |
| WO2004039834A2 (en) | 2004-05-13 |
| PL375218A1 (en) | 2005-11-28 |
| WO2004039834A3 (en) | 2004-08-26 |
| AU2003275941A1 (en) | 2004-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090054625A1 (en) | Recombinant protein variants | |
| KR100919914B1 (ko) | 신규한 돌연변이체 알레르겐 | |
| Tscheppe et al. | Recombinant allergens in structural biology, diagnosis, and immunotherapy | |
| CA2319437C (en) | Methods and reagents for decreasing allergic reactions | |
| CN1332029C (zh) | 突变的重组过敏原 | |
| JP2004521618A5 (https=) | ||
| Saarne et al. | Rational design of hypoallergens applied to the major cat allergen Fel d 1 | |
| CN104203277A (zh) | 梯牧草变应原和用于调节免疫反应的方法和用途 | |
| PL212139B1 (pl) | Zrekombinowany alergen, zastosowanie zrekombinowanego alergenu, kompozycja zawierająca dwa lub więcej wariantów zrekombinowanych zmutowanych alergenów, zastosowanie takiej kompozycji, kompozycja farmaceutyczna zawierająca zrekombinowany alergen lub wymienioną kompozycję, zastosowanie zrekombinowanego alergenu, kompozycji lub kompozycji farmaceutycznej, sposób przygotowania kompozycji farmaceutycznej, sposób przygotowania zrekombinowanego alergenu, sposób przygotowania biblioteki zrekombinowanego alergenu, sekwencja DNA kodująca zrekombinowany alergen, wektor ekspresyjny obejmujący wymienione DNA, komórka gospodarza zawierająca taki wektor ekspresyjny, sposób produkcji zrekombinowanego mutanta alergenu, oraz oznaczenie diagnostyczne do oceny odpowiedniości, bezpieczeństwa lub wyniku terapii | |
| PL196830B1 (pl) | Modyfikowane alergeny rekombinacyjne pyłku Graminae, sposób ich otrzymywania, zawierające je preparaty farmaceutyczne i sposób ich otrzymywania oraz ich zastosowanie do immunospecyficznej terapii alergii i wytwarzania leków do immunospecyficznej terapii alergii | |
| US6335020B1 (en) | Allergenic peptides from ragweed pollen | |
| CA2649057A1 (en) | Phl p 1 allergen derivative | |
| RU2285042C2 (ru) | Новые мутантные аллергены | |
| KR101019865B1 (ko) | ＩｇＥ 결합이 감소되었지만, Ｔ-세포 항원성은 저하되지않은 재조합 알레르겐 | |
| JP7505788B2 (ja) | Ｃ９ｏｒｆ７２に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト | |
| EP1558740A2 (en) | Recombinant protein variants | |
| HK1152729A (en) | Recombinant protein variants | |
| US9446121B2 (en) | Cloning of honey bee allergen | |
| EP1369483A1 (en) | Allergen from mugwort pollen | |
| CN102811735B (zh) | 由于脯氨酸残基突变而具有降低的致敏性的禾本科的第6组过敏原的变异体 | |
| ES2384231T3 (es) | Proteínas híbridas de pincipales alérgenos de Parietaria judaica y usos de las mismas | |
| Ruffilli et al. | Characterization of a Dominant Epitope of the Major Allergens of Parietaria | |
| HK40022726B (zh) | Tau肽免疫原构建体 | |
| JP2005168506A (ja) | マラセチア由来の抗原性蛋白質 | |
| JP2002058487A (ja) | 新規なスギ花粉アレルゲン遺伝子および該遺伝子がコードするタンパク質またはその抗原性断片 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060921 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060921 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090917 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090929 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100308 |